Immunotherapies have led to the successful development of novel therapies for cancer. However, there is increasing concern regarding the adverse effects caused by non-tumor-specific immune responses. Here, we report an effective strategy to generate high-avidity tumor-antigen-specific CTLs, using Cas9/single-guide RNA (sgRNA) ribonucleoprotein (RNP) delivery. As a proof-ofprinciple demonstration, we selected the gp100 melanoma-associated tumor antigen, and cloned the gp100-specific high-avidity TCR from gp100-immunized mice. To enable rapid structural dissection of the TCR, we developed a 3D protein structure modeling system for the TCR/antigenmajor histocompatibility complex (pMHC) interaction. Combining these technologies, we efficiently generated gp100-specific PD-1(−) CD8 + T cells, and demonstrated that the genetically engineered CD8 + T cells have high avidity against melanoma cells both in vitro and in vivo. Our methodology offers computational prediction of the TCR response, and enables efficient generation of tumor antigen-specific CD8 + T cells that can neutralize tumor-induced immune suppression leading to a potentially powerful cancer therapeutic.
Introduction
Recently, immunotherapies have led to the successful development of novel treatments for cancer, primarily by two strategies, immunologic checkpoint blockade therapy and adoptive T-cell therapy (1) (2) (3) . Although immunotherapies targeting immune checkpoints, such as with anti-CTLA-4 and anti-PD-1 antibodies, have shown promising efficacy in the treatment of cancer, immune-related adverse events (irAEs) have been reported, possibly due to enhanced systemic immunity against non-tumor cells (1, (4) (5) (6) (7) . In the case of adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes and genetically modified T cells, such as antigen-specific chimeric antigen receptor (CAR) or antigen-specific TCR-transduced T cells, several potential risk factors for irAEs elicited by the non-tumor-specific reaction of the artificial antigen-receptor and by the exogenous TCR have been noted (2, (8) (9) (10) (11) . Furthermore, the tumor microenvironment reportedly induces the expression of immunologic checkpoint genes on transferred tumor-specific T cells and impairs the therapeutic effects of these transplanted cells (12) . These critical problems must be solved for these therapies to be broadly applicable and safe for clinical use. One potential approach to surmounting these problems is to exploit a highly efficient genome editing technique in CD8 + T cells that enables the easy generation of tumor-antigen-specific CD8 + T cells.
The CRISPR/Cas9 system has emerged as a game-changing technology for genome engineering (13) (14) (15) . However, its application is still limited, due to the lack of efficient gene transfer techniques and the low efficiency of genome editing in some cell types (16) (17) (18) . In fact, genome editing in primary lymphocytes could not be achieved by standard gene delivery methods (16) (17) (18) . The usefulness of various techniques for the delivery of Cas9 ribonucleoproteins [RNPs; recombinant Cas9 protein complexes with a single-guide RNA (sgRNA)] has been recently demonstrated, toward overcoming this issue (17, 19, 20) . However, significant improvements are still needed for primary lymphocytes.
For the successful and safe targeting of tumor cells using CTLs, rapid identification and verification of the optimal cancer-antigen-specific TCR is the critical process for cancer patients requiring urgent treatment. However, the isolation of high-avidity tumor-specific lymphocytes from a cancer patient is a difficult and often time-consuming process, and the cloning of the high-avidity tumor-specific TCR is arduous. Moreover, while structure determination by X-ray crystallography of the tumor-antigen-specific TCR and the antigenmajor histocompatibility complex (pMHC) is desirable to verify the molecular function and the quality of the TCR for the optimal clinical application, it is also notoriously difficult, costly and time-consuming, because of the relatively low affinity of the TCR and pMHC interaction (21) .
To develop clinically applicable methods for the successful targeting of tumor cells using adoptive T-cell therapy, progress in the development of in silico-based immune response predictions and highly efficient genome editing techniques in primary CD8 + T cells are eagerly awaited.
Methods

Mice
Female C57BL/6J mice aged 8-10 weeks were obtained from Japan SLC, Inc. (Shizuoka, Japan). All animal experiments were approved by the Animal Care Committees of the Institute of Medical Science, The University of Tokyo and Chiba University.
Generation of gp100-reactive T cells
C57BL/6 mice were immunized subcutaneously (s.c.) with 110 μg of gp100 (MBL, Nagoya, Japan) and 120 μg of helper peptide (MBL), emulsified in complete Freund's adjuvant (CFA) (Detroit, MI, USA). Three weeks after immunization, the mice were boosted with 110 μg of gp100 and 120 μg of helper peptide, emulsified in incomplete Freund adjuvant (IFA) (Difco). Three weeks after boosting, the spleens were harvested, and the red blood cells were lysed. Splenocytes were cultured with mitomycin-C-treated splenocytes in CTL media [50 μM 2-mercaptoethanol (Nacalai tesque, Kyoto, Japan), 2 mM l-glutamine (Nacalai tesque), 1% non-essential amino acids (Nacalai tesque), 20 mM HEPES (Nacalai tesque), 10% fetal bovine serum (GE Healthcare, Chicago, IL, USA), RPMI (Nacalai tesque)], supplemented with 1 μM of gp100 and 20 ng ml −1 rmIL-2 (R&D Systems, Abingdon, UK). The cells were cultured for over 6 weeks until further experiments. For the clonal expansion analysis, gp100-Tetramer + T cells were single-cell-sorted by FACS Aria (Franklin Lakes, NJ, USA) and co-cultured with CD11c + splenocytes in the presence of the gp100 peptide.
TCR repertoire analysis
Unbiased TCRα and TCRβ analyses were performed using the originally modified SMART ('switching mechanism at 5′ end of RNA template') method. Reverse transcription was performed using the TCR-SMART oligonucleotide, Tcra RT or Tcrb RT primers, and SMART Scribe RTase (Mountain View, CA, USA), at 42°C for 90 min. Doublestranded cDNA was then synthesized, and amplified with TCRα and TCRβ gene-specific primers. The amplified cDNA was used as templates in TCRα-or TCRβ-specific amplifications. The PCR products were then cloned into the pGEM-TEasy Vector (Madison, WI, USA) and sequenced. To detect TRAV4-3-TRAJ27-TRAC and TRBV13-1-TRBJ1-2-TRBC gene expression, specific PCR primer sets were designed for each of these genes. The sequences of oligonucleotides are listed in Supplementary Table 1, available at International Immunology Online.
3D modeling of the TCR-MHC-gp100 peptide complex
The comparative protein modeling approach was used to generate 3D structures of the TCR-MHC-gp100 peptide complex. All sequence alignments were performed using MUSCLE (22) . The template X-ray crystal structure used to model the cloned TCRα and TCRβ sequences (PDB: 2CKB) (23) was identified using FFAS (24) . The sequences were modeled using the positions from the template structures, followed by side-chain optimization using SCWRL (25) . A library of loop regions was modeled with MODELLER (26) and the conformations were manually selected for further docking. The structures of the TCRα and TCRβ proteins were independently modeled. The modeled structures were docked to generate a model of the TCRα/β complex. The best TCRα/β complex was selected through manual inspection of the hydrogen bonds formed between the two TCR subunits and the distance between their CDR3 loops. This complex was further docked onto the crystal structure of the gp100-H2-Db complex (PDB: 3CC5) (27) .
Generation of tumor antigen-specific CD8 + T cells
Docking was performed using the ClusPro web server (28, 29) which returns clusters of 1000 low-energy docking results. The best docked complex structures were manually selected through the visual inspection of the number of hydrogen bonds formed between the TCRα/β complex and the MHC-gp100 complex, and the relative orientation between the two complexes. Visualization and structural analysis of the 3D structures were performed using Chimera (University of California, San Francisco; UCSF, CA, USA). The electrostatic potential of the protein is colored as follows: negatively charged amino acids, red; positively charged amino acids, blue; and hydrophobic residues, gray. For the schematic representation of CDR3, amino acids are colored according to the Zappo color scheme.
Construction of plasmid vectors
To construct the sgRNA-coding template plasmid, named pGEM-T-Easy-T3-BB-sgRNA, the complementary oligonucleotides T3-BB-sgRNA-F and T3-BB-sgRNA-R were phosphorylated using T4PNK (Takara Bio Inc., Shiga, Japan), annealed and cloned into the pGEM-T-Easy Vector (Promega). For the construction of the plasmid encoding the mouse Trac, mouse Trbc and mouse PD-1 sgRNAs, the respective complementary oligonucleotides were phosphorylated using T4PNK (Takara Bio Inc. Japan), annealed and cloned into the pGEM-T-Easy-T3-BB-sgRNA plasmid via the BbsI restriction site. To construct the retroviral vector plasmid encoding the gp100-specific TCRα and TCRβ, the cDNAs were subcloned into the suitable restriction sites of the pMX-MCS-IRES-EGFP vector. The sequences of oligonucleotides are listed in Supplementary  Tables 2 and 3 , available at International Immunology Online.
In vitro transcription of sgRNA
For the in vitro synthesis of sgRNAs, each template sgRNA plasmid (3 μg) was linearized by DraI and transcribed in vitro with T3-RNA polymerase in a final volume of 40 μl, according to the manufacturer's protocol (Promega). The RNA transcripts were purified by digestion with 1 U of TURBO DNase (Thermo Fisher Scientific, MA, USA) at 37°C for 30 min, extracted with phenol:chloroform, and subjected to ethanol precipitation with ammonium acetate. The RNA pellet was then washed and resuspended in RNase-free water, and stored at −80°C.
Electroporation
CD8
+ T cells were purified from whole splenocytes using MACS columns (Bergisch, Gladbach, Germany), and stimulated with 20 ng ml −1 rmIL-2 (R&D Systems) and Dynabeads mouse T-Activator CD3/CD28 (Thermo Fisher Scientific). Forty-eight hours after stimulation, 2 × 10 5 CD8 + T cells were washed with PBS and re-suspended in 5 μl of buffer R (Neon Kit, Thermo Fisher Scientific). For the transduction of GFP, 1 μg of recombinant GFP was mixed with buffer R, in a final volume of 10 μl. A 10-μl aliquot of the cell suspension was electroporated with a Neon electroporation device, according to the manufacturer's protocol (Thermo Fisher Scientific; 1700 V, 10 ms, three pulses). The cells were cultured in CTL medium supplemented with 20 ng ml −1 rmIL-2 for 2 h, until further experiments. The recombinant SpCas9 protein bearing a nuclear localization was prepared as described previously (30) . For the preparation of SpCas9/sgRNA RNP complexes, 1 μg of purified recombinant SpCas9 protein and 300 ng of sgRNA were pre-incubated in 5 μl of buffer R, for 10 min at room temperature. The cell suspensions were then mixed with buffer R containing the Cas9 RNPs, to a final volume of 10 μl. A 10-μl aliquot of the cell suspension was electroporated with a Neon electroporation device (1700 V, 10 ms, three pulses). After electroporation, the cells were immediately plated into in 24-well plates containing (per well) 500 μl of pre-warmed CTL medium, supplemented with 20 ng ml −1 rmIL-2, 5 ng ml −1 rmIL-7 (R&D Systems), 5 ng ml −1 rmIL-15 (Rocky Hill, NJ, USA) and Dynabeads mouse T-Activator CD3/ CD28, and incubated in a 5% CO 2 incubator. The cells were cultured over 2 days until further experiments.
Flow cytometry and cell sorting
Cell-surface staining was performed with αCD8-FITC (KT15, MBL), αTCR-APC (H57-597, eBioscience, CA, USA), αPD-1-PE (J43, BD Biosciences, CA, USA), αIFN-γ (XMG1.2, eBioscience), αIL-2 (JES-5H4, eBioscience), αTNF-α (MP-XT22, eBioscience), αGranzyme B (GB11, eBioscience), αEOMES (Dan11mag, eBioscience), αTbet (eBio4B10, eBioscience) and αCD107a (1D4B, Biolegend, CA, USA) for 20 min on ice. Cell viability was examined by 7-amino-actinomycin D (7-AAD) (BD Biosciences) staining. For tetramer staining, cells were stained with T-Select H-2Db gp100 Tetramer-KVPRNQDWL-APC (MBL), according to the manufacturer's instructions. For intracellular staining, cells were fixed in 4% paraformaldehyde and permeabilized with 0.01% Triton X-100 in PBS. The cells were then stained with αSpCas9 (bD-20, Santa Cruz, CA, USA) and visualized with an Alexa Fluor 488-conjugated secondary antibody (Thermo Fisher Scientific). All samples were analyzed with a FACS Caliber (Becton Dickinson) flow cytometer. Cells were sorted using a FACS Aria (Becton Dickinson) cell sorter.
Retroviral production and transduction
Retroviral vectors encoding TCR genes were produced as follows. The transient retrovirus packaging cell line PLAT-E (31) was transfected with the retrovirus vector plasmid, using the FuGene6 transfection reagent (Roche, Mannheim, Germany). Two days after transfection, cell supernatants were harvested and concentrated by centrifugation in a centrifugal filter device (Billerica, MA, USA). Genome-edited CD8 + T cells were seeded onto retronectin (Takara Bio Inc.)-coated plates, suspended in retroviral solution supernatant with 20 ng ml −1 rmIL-2, 5 ng ml −1 rmIL-7 and 5 ng ml −1 rmIL-15, and centrifuged at 2000 × g for 120 min at 32°C. The transduction was repeated the following day, and the cells were cultured in IL-2-, IL-7-and IL-15-containing medium for 24 h. The gp100-reactive cells were then selectively expanded by co-culturing with GM-CSF-induced bone-marrow-derived dendritic cells (BMDCs) in CTL medium, supplemented with 1 μM of gp100 and 20 ng ml −1 rmIL-2. The cells were cultured for 1 week until further experiments.
T7 endonuclease I cleavage assay
Genome editing efficiency was examined by T7 endonuclease I (T7EN1) cleavage assays. Genomic regions surrounding the target sites and the potential off-target sites of sgRNAs were amplified by PCR, using Takara ExTaq (Takara Bio Inc.). Gelpurified PCR products (200 ng) were re-suspended in NEB , 25°C for 30 s, and hold at 4°C. Five units of T7EN1 (NEB, MA, USA) were added to digest the reannealed DNA at 37°C. After 2 h, the DNA products were resolved on 2% agarose gels. Bands were visualized with ethidium bromide. Percentages of indels were examined by the Image J software. The sequences of primers are listed in Supplementary  Tables 4 and 5 , available at International Immunology Online.
In vitro cytotoxic assay
The in vitro cytotoxic activity of CD8 + T cells against B16 melanoma cells was examined, based on the release of LDH measured using the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega) according to the manufacturer's instructions. Briefly, 1 × 10 4 B16 cells were plated onto 96-well plates and co-cultured for 18 h with various ratios of CD8 + T cells. The MACS-sorted naive CD8 + T cells were used for control experiments. Lactate dehydrogenase (LDH) release was measured as the percentage of LDH released in the culture media relative to the total LDH.
Cell proliferation assay
The TCR-transduced CD8 + T cells (2 × 10 4 ) were co-cultured with 2 × 10 4 ovalbumin (OVA)-or gp100-pulsed GM-CSFinduced BMDCs. The number of CD8 + cells was monitored by flow cytometry.
In vivo tumor challenge and adoptive cell transfer
B16 melanoma cells were collected by trypsinization and washed with PBS. Mice were anesthetized prior to the tumor challenge, and 5 × 10 5 B16 melanoma cells in a total volume of 100 μl of HBSS were implanted into the subcutaneous tissue, using a 27-G needle. At day 6 after implantation, mice were irradiated with 5 Gy. On the next day, groups of mice underwent tail vein injections of 1 × 10 6 CD8 + T cells and subcutaneous injections of 5 × 10 5 GM-CSF-induced BMDCs, and 100 000 IU of rmIL-2 was administered twice daily for 3 days via intra-peritoneal injection. The MACS-sorted naive CD8 + T cells were used for control experiments. The perpendicular diameters of the tumors were measured with a digital caliper, and the tumor volume was calculated using the following formula: V = D × d2 × 0.52 (V: volume of the tumor; D:
Statistical analysis
Statistical significance was evaluated using the two-tailed Student's t-test and the ANOVA with post hoc Bonferroni correction. Values are expressed as means ± SEM. Data represent means ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001; NS indicates not significant.
Results
Generation of gp100 melanoma-associated tumor-antigen-specific CTLs
To establish an efficient strategy for generating high-avidity tumor-reactive CTLs using CRISPR/Cas9, we used the spontaneous C57BL/6-derived B16 melanoma as a wellestablished human malignant tumor model (32) . First, to obtain B16 melanoma-reactive CTLs, since immunization with the human homologue of the melanoma-associated antigen, the gp100 peptide, has previously been used as a conventional method to induce B16 melanoma-reactive CTLs (33, 34) , we immunized mice with the gp100 peptide and then induced and expanded gp100-Tetramer + CD8 + T cells by stimulation with the gp100 peptide in vitro (Fig. 1A) . Next, to examine the cytotoxic activity of the induced gp100-Tetramer + CD8
+ T cells against melanoma cells in vivo, we transferred the gp100-Tetramer + CD8 + T cells adoptively into B16 tumorbearing mice. The group of mice adoptively transferred with gp100-Tetramer + CD8 + T cells showed a significant reduction in tumor growth, as compared with control mice (Fig. 1A) . The gp100-Tetramer + CD8 + T cells can be divided into two distinct populations (Fig. 1B) . When we examined the difference in the biological activities between the gp100-Tetramer Lo and gp100-Tetramer Hi CD8 + T cells, the amount of IFN-γ secretion by gp100-Tetramer Hi CD8 + T cells was significantly enhanced by the co-culture with B16 cells, as compared with that secreted by gp100-Tetramer Lo CD8 + T cells (Fig. 1C) . The in vitro killing assay confirmed that the CTL killing activity of gp100-Tetramer Hi CD8 + T cells against B16 cells was much greater than that of gp100-Tetramer Lo CD8 + T cells (Fig. 1D) .
Identification of gp100 antigen-specific TCRα/β sequences from gp100-Tetramer + CD8 + T cells
To identify the gp100 antigen-specific TCR sequences from the gp100-Tetramer + CD8 + T cells, we used an unbiased TCR cloning approach, in which the switching mechanism at the 5′-terminus of the RNA transcript (SMART) is used to synthesize cDNA from all expressed TCRα and TCRβ mRNAs (Supplementary Figure 1 , available at International Immunology Online). Analysis of the TCR repertoires of the gp100-Tetramer Hi CD8 + T-cell population revealed the major TCR clonotype (Fig. 2A) . The amino acid sequence comparison of the complementarity-determining region 3 (CDR3) antigen-recognition site revealed that the TCRα and TCRβ chains display a tendency to contain negatively charged residues (glutamic acid and aspartic acid) and polar residues on the tips of their CDR3s, respectively ( Fig. 2A) . In contrast, the TCRβ chains in the gp100-Tetramer Lo CD8 + T cells are different from those in the gp100-Tetramer Hi CD8 + T cells (Fig. 2B) . Next, to identify the TCRα/β pair of the high-avidity CD8 + T cells specific to the gp100 antigen, we sorted single gp100-Tetramer Hi CD8 + T cells, clonally expanded the cells in vitro and then examined the composition of the TCR repertoires of the cells. Notably, >80% of the clones expressed the same pair of TCRα/β chains (TRAV4-3-TRAJ27; TRBV13-1-TRBJ1-2) (Fig. 2C) . The expression level of IFN-γ in this gp100-stimulated CD8 + T-cell clone was significantly higher than the levels observed in the other CD8 + T-cell clones (Fig. 2D) .
Rapid computational prediction of gp100-specific TCR-gp100 antigen-MHCI protein complex
To achieve rapid molecular dissection of the cloned antigenspecific TCR for optimal clinical application, we developed a computational method to predict the 3D structures of the Figure 2C and E, available at International Immunology Online). In addition, consistent with a previous study by Denton et al. (35) , the structure model demonstrated the importance of the asparagine residue in the fourth position of the OVA peptide for the binding of OT-I TCR. This confirmed the validity of our computational approach. Next, we analyzed the binding of the gp100-specific TCR to the gp100 antigen-H-2Db complex, using the same 3D protein structure modeling approach. Again, consistent with the theoretical binding mode, our gp100-specific TCR model indicated that the gp100-specific TCR precisely binds to the surface H2-Db residues adjacent to the bound gp100 peptide ( Fig. 3A-C ; Table 1 ). Five hydrogen bonds, including the three bonds between CDR3 and the gp100 peptide (α91Thr to p4Arg, α90Asp to p4Arg, β93Thr to p6Gln), are observed between the TCR and the gp100 peptide ( Fig. 3B; Table 1 ). A comparison of this structural model with that of a clone expressing a low level of IFN-γ (TRAV4-3-TRAJ27; TRBV13-1-TRBJ2-1) showed that the threonine residues in the CDR3β are conserved between them (Fig. 3D) ; however, the CDR3β of the IFN-γ low-expressing clone is longer and lacks the gp100-interacting charged residues (Fig. 3E-I) . Together, our computational analysis demonstrates the structural aspects of the IFN-γ high-expressing TCR clone underlying its antitumor activity.
Efficient genome editing of TCR gene in primary CD8 + T cells via Cas9 RNP delivery
Although CRISPR/Cas9 enables efficient genome editing, its applications are still limited owing to the lack of efficient delivery techniques in some cell types. Indeed, genome editing in CD8 + T cells remains challenging, and we could not achieve genome editing using standard methods, such as plasmid transfection and lentiviral transduction. To overcome this difficulty, we took advantage of protein delivery techniques. First, to achieve highly efficient protein transduction 
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in CD8 + T cells, IL-2/CD3/CD28-stimulated CD8 + T cells were subjected to electroporation-based GFP delivery at various conditions and time points. From this result, we found that >90% of the CD8 + T cells are highly amenable to electroporation-mediated protein delivery at 48 h post-stimulation, without severely affecting cellular viability (Fig. 4A-D) . To change the antigen specificity of CD8 + T cells, we designed and in vitro transcribed sgRNAs targeting a constant region of the TCRα/β genes in vitro, to eliminate endogenous TCRα/β gene expression ( Fig. 4E and F) .
To achieve highly efficient genome editing in T lymphocytes, we purified and prepared recombinant Streptococcus pyogenes Cas9 (SpCas9), bearing two nuclear localization signal sequences fused to the C-terminus, without glycerol supplementation as described previously (30) . The recombinant SpCas9 was incubated with each gRNA, and then the pre-formed Cas9/gRNA RNP complexes were delivered into IL-2/CD3/CD28-stimulated CD8 + T cells by electroporation (Fig. 4G) . Using this method, we successfully transduced Cas9 RNPs into CD8 + T cells with almost 100% efficiency ( Fig. 4H and I ). The transduction of Cas9 RNPs targeting the TCRα/β genes drastically reduced the expression of the TCR from 48 h after electroporation ( Fig. 4J and K) . The results of T7EN1 cleavage assays confirmed that the target sites are edited at >90% efficiency (Fig. 4L) . Notably, all of the TCR knockout cells had multiple mutations in the Tcra, Trbc1 and Trbc2 genes, demonstrating that this system enables multiplex genome editing with an efficiency of almost 100% ( Fig. 4M-P) .
Generation of PD-1 knockout CD8 + T cells using Cas9 RNP delivery
To generate high-avidity CD8 + T cells, we further sought to target the immune checkpoint gene PD-1. As previously reported, the expression of the PD-1 ligand, PD-L1, was observed in B16 melanoma cells (Fig. 5A) . The expression of PD-1 was up-regulated upon CD3/CD28 stimulation in CD8 + T cells (Fig. 5B and C) . The PD-1-specific gRNA was designed 
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to target the Exon2 region, and the Cas9/PD-1 gRNA RNP was electroporated into CD8 + T cells (Fig. 5D) . After 3 days, significantly reduced expression of PD-1 was observed in the Cas9/PD-1 gRNA RNP-transduced cells (Fig. 5E-G) . The results of the T7EN1 cleavage assay and the sequence analysis confirmed that the target site was efficiently disrupted in these cells (Fig. 5H and I) .
Recently, because of the rapid degradation of the Cas9 RNP complex, it has been accepted that the off-target effects of Cas9 RNP are lower than those of the conventional gene delivery methods (17) . Next, we analyzed the off-target effects of the gRNAs targeting Trac, Trbc and Pd-1 using the conventional T7EN1 assay and PCR direct sequencing. Since we designed and selected the gRNAs with minimized off-target candidates, these gRNAs lack potential off-target sites with 1-or 2-nt mismatches (Supplementary Figure 3A 
Generation of gp100-specific PD-1 knockout CD8 + T cells via Cas9 RNP delivery
By combining these technologies, we generated gp100-specific PD-1-deficient CD8 + T cells (Fig. 6A) . After the transduction of Cas9 RNPs, TCRα/β-and PD-1-deficient CD8 + T cells were isolated and then transduced with a retrovirus encoding a cloned gp100-specific TCR gene (Fig. 6A and B) . Following the selective expansion of the gp100-reactive genome-edited CD8 + T cells using the gp100 peptide ( Fig. 6A and C) , the expression of the gp100-specific TCR by TCR(−)PD-1(+) CD8 + T cells and TCR(−)PD-1(−) CD8 + T cells was confirmed by gp100-tetramer staining (Fig. 6D) . To examine whether these genetically engineered CD8 + T cells display the characteristic features of CTLs, we assessed the expression of IL-2, IFN-γ, TNF-α, Granzyme B, T-bet, Eomes and CD107a. The expression of these CTL markers was also observed in these cells (Fig. 6E and F) . 148 Generation of tumor antigen-specific CD8 + T cells 
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gp100-specific PD-1-knockout CD8 + T cells exhibit enhanced anti-tumor efficacy against melanoma both in vitro and in vivo
Finally, to examine the anti-tumor activity of the genetically engineered PD-1-deficient gp100-specific CD8 + T cells against gp100-positive melanoma cells, we generated gp100-specific CD8 + T cells with or without PD-1 gene disruption, and the anti-tumor activities of the gene-edited CD8 + T cells were assessed by both in vitro and in vivo killing assays using B16 cells (Fig. 7A-C) . The results of the in vitro killing assay demonstrated that the PD-1-deficient gp100-specific CD8 + T cells exhibit significantly enhanced cytotoxic activity against B16 cells, as compared with the PD-1(+) gp100-specific CD8 + T cells (Fig. 7A) . Consistent with the in vitro killing assay results, the level of IFN-γ expression is significantly up-regulated in the PD-1-deficient gp100-specific CD8 + T cells (Fig. 7B) . To examine the anti-tumor activity against B16 cells in vivo, we transferred these genetically engineered gp100-specific CD8 + T cells adoptively into B16 tumor-bearing mice. The tumor volume of B16 cells was significantly reduced by the tail vein injection of PD-1-deficient gp100-specific CD8 + T cells, as compared with the group of mice adoptively transferred with PD-1(+) gp100-Tetramer + CD8 + T cells (Fig. 7C) . No detectable adverse effects were observed in the mice injected with these genetically engineered gp100-specific CD8 + T cells. These results indicate that CRISPR/Cas9-mediated PD-1 gene disruption can enhance the cytotoxicity of tumor antigen-specific CD8 + T cells against tumor cells both in vitro and in vivo.
Discussion
In this study, we used a combination of computational protein modeling and genome editing to maximize the therapeutic efficacy of cancer immunotherapy and minimize the risk of irAEs. Currently, anti-PD-1 immunotherapies are the most promising therapeutic approach for advanced melanoma (1, 5) . However, cumulative results have revealed the risk of 
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injected with the genetically engineered gp100-specific CD8 + T cells. Since our approach enables the disruption of the PD-1 gene only in melanoma-specific CD8 + T cells, as compared with the therapy using the systemic administration of immune checkpoint inhibitors, this approach both maximizes the therapeutic efficacy of the melanoma-specific CD8 + T cells and reduces the likelihood of any irAE-like symptoms in mice transplanted with PD-1-deficient CD8 + T cells. Recently, Ren et al. (36) reported the enhanced immune activity of the CAR T cells by deleting the PD-1 and TCR gene in human CD8 + T cells. However, since the cytokine release syndrome (CRS) is the most prevalent adverse effect in the CAR T-cell therapy (11) , there remain certain risks of causing CRS. Thus, our approach targeting the PD-1 gene of tumor antigen-specific CD8 + T cells can improve the therapeutic efficacy and reduce the risk of irAEs in cancer immunotherapies applied to humans. However, on-target off-tumor toxicity is often debated in the adoptive T-cell therapy (11), so careful selection of tumor-antigen-specific TCRs is needed for achieving success with the genetically engineered CD8 + T cells. Recently, CRISPR/Cas9-mediated genome editing using the Cas9 RNP delivery has been reported by several groups (17, 19, 20) . However, it is still difficult to achieve efficient genome editing in primary blood-derived cells. In this study, we prepared the high-purity recombinant SpCas9 protein and achieved highly efficient genome editing in CD8 + T cells, by careful optimization of the timing after the CD3/CD28 stimulation and the electroporation conditions. Since we could not generate the knockout CD8 + T cells with sufficient efficiency using the commercially available SpCas9 proteins, we speculate that some additives, such as salt and glycerol, in the protein solution critically affect the efficiency of genome editing. Our data demonstrated that, unlike plasmid transfection approaches, the direct delivery of Cas9 RNPs is a rapid and highly efficient way to modify cellular function. Importantly, although the off-target cleavage by CRISPR/Cas9 has often been disputed (37), we did not observe any significant offtarget effect by this method. Since the Cas9/gRNA RNP might act first and turn over rapidly, the probability of off-target cleavage is expected to be lower, as compared with conventional DNA-based genome editing methods (17) . Moreover, since Cas9/gRNA RNP delivery eliminates the potential risks of unpredictable genetic integration of the genome editing tool from plasmid and viral vectors, this method may enable clinically safe and effective cell engineering.
In addition, our novel approach using computational modeling of the TCR/pMHC complex enables the rapid in silico evaluation of the tumor-antigen-specific TCR, as compared with current standard methods using X-ray crystallography. Although X-ray crystallography is an important and powerful tool for protein structure determination, it is costly and time-consuming, and not all proteins can be successfully crystallized. Since the binding affinity of TCR to pMHC is relatively low (21) , structure determination of the tumor-antigen-specific TCR/pMHCI complex is a difficult, and obviously unrealistic process for clinical applications and high-throughput analyzes of large numbers of samples. Thus, novel approaches using computational modeling are eagerly sought. Thanks to the recent expansions of protein structure databases, our unique system enables the rapid and precise prediction of the TCR/pMHCI complex structure, by using the 70 experimentally determined mouse and human 3D macromolecular structure data available in public databases. In addition, this system is automatable, and we envision future applications in sequence-based high-throughput screening and identification of tumor-antigen-specific human TCRs, for the successful targeting of tumor cells using CTLs. Our approach further enabled the generation of tumor-antigen-specific cytotoxic T cells, using highly efficient genome editing in CD8 + T cells. In conclusion, using a combination of genome editing and computational modeling tools, we developed a highly specific, safe and widely applicable anti-cancer therapeutic method. Our methodology opens up new avenues toward efficient and safe strategies to generate high-avidity tumorspecific lymphocytes for potential use in humans.
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